文献速递淋巴瘤

抑制IL-10增强慢性淋巴细胞白血病T细胞抗肿瘤免疫及检查点阻断应答

Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2021-03-17

慢性淋巴细胞白血病(CLL)中T细胞功能障碍与IL-10等抑制性分子相关,且多数患者对免疫检查点阻断(ICB)反应不佳。研究使用Sp1抑制剂类似物MTMox32E抑制CLL细胞IL-10产生,在体外维持T细胞效应功能,在Eμ-Tcl1小鼠模型中降低血浆IL-10和CLL负荷并增强CD8+ T细胞功能。联合抗PD-L1时,CLL细胞负荷较单用抗PD-L1降低4.5倍,并增加干扰素-γ+、细胞毒性效应KLRG1+和记忆CD8+ T细胞、减少耗竭T细胞。

要点

  • MTMox32E抑制小鼠和人CLL细胞IL-10产生并维持体外T细胞效应功能。
  • Eμ-Tcl1小鼠中降低血浆IL-10和CLL负荷,增加CD8+ T细胞增殖、效应/记忆及干扰素-γ。
  • 联合抗PD-L1使CLL细胞负荷较单药降低4.5倍,并减少耗竭T细胞。

核心结论

  • 抑制IL-10可增强抗肿瘤T细胞活性并改善CLL对ICB的应答,为不靶向IL-10的现有CLL治疗提供新策略。

研究设计与样本

  • 研究使用Sp1抑制剂类似物MTMox32E抑制CLL细胞IL-10,并在体外及Eμ-Tcl1小鼠模型中评估T细胞功能与ICB联合效果。

主要发现

  • MTMox32E抑制小鼠和人CLL细胞IL-10产生并在体外维持T细胞效应功能。
  • Eμ-Tcl1小鼠中治疗降低血浆IL-10和CLL负荷,增加CD8+ T细胞增殖、效应和记忆细胞比例及干扰素-γ产生。
  • 联合抗PD-L1时CLL细胞负荷较单用抗PD-L1降低4.5倍,并增加干扰素-γ+、细胞毒性效应KLRG1+和记忆CD8+ T细胞、减少耗竭T细胞。

临床怎么用

  • 抑制IL-10可能作为增强CLL免疫检查点阻断疗效的联合策略,但需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell dysfunction is a hallmark of B-cell Chronic Lymphocytic Leukemia (CLL), where CLL cells downregulate T-cell responses through regulatory molecules including programmed death ligand-1 (PD-L1) and Interleukin-10 (IL-10). Immune checkpoint blockade (ICB) aims to restore T-cell function by preventing the ligation of inhibitory receptors like PD-1. However, most CLL patients do not respond well to this therapy. Thus, we investigated whether IL-10 suppression could enhance antitumor T-cell activity and responses to ICB. Since CLL IL-10 expression depends on Sp1, we utilized a novel, better tolerated analogue of the Sp1 inhibitor mithramycin (MTMox32E) to suppress CLL IL-10. MTMox32E treatment inhibited mouse and human CLL IL-10 production and maintained T-cell effector function in vitro. In the Eμ-Tcl1 mouse model, treatment reduced plasma IL-10 and CLL burden and increased CD8+ T-cell proliferation, effector and memory cell prevalence, and interferon-γ production. When combined with ICB, suppression of IL-10 improved responses to anti-PD-L1 as shown by a 4.5-fold decrease in CLL cell burden compared to anti-PD-L1 alone. Combination therapy also produced more interferon-γ+, cytotoxic effector KLRG1+, and memory CD8+ T-cells, and fewer exhausted T-cells. Since current therapies for CLL do not target IL-10, this provides a novel strategy to improve immunotherapies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Rivas JR, Liu Y, Alhakeem SS, et al. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia. Leukemia. 2021. PMID: 33731852. doi:10.1038/s41375-021-01217-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。